Novartis statement on the conclusion of the hearing regarding the Glivec patent before the Supreme Court of India

Novartis statement on the conclusion of the hearing regarding the Glivec patent before the Supreme Court of India


The hearing of the special leave petition filed by Novartis before the Supreme Court of India regarding the "Glivec patent" concluded on Tuesday, 4 December 2012.

Novartis deeply appreciates the opportunity to present the case before the Court and will look forward to the outcome. Novartis pursued the litigation with a view to seek clarity on the unique aspects of India's patent law and to foster an innovative environment to the benefit of patients.

The verdict and the timing of its ruling are entirely at the discretion of the court. We expect to have a decision sometime before the end of Q1 of 2013.

Suggested Articles

GlaxoSmithKline, its agency McCann Health, and their "Breath of LIfe" smartphone app took the Grand Prix in pharma last night at Cannes Lions Health.

P&G, the packaged goods giant that bought Merck KgAA’s consumer unit, is out in force at Lions Health. Is that a message for rivals?

Jazz Pharma's next drug launch is set for early July after a DEA scheduling for sleepiness drug Sunosi.